VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if, in type 2 diabetic patients undergoing
treatment with PCI and a stent, who fail to respond to normal doses of clopidogrel, a loading
dose of 60 mg of prasugrel followed by 10 mg once daily is superior to the standard dose of
75 mg of clopidogrel in achieving greater than 50% inhibition of platelet aggregation at
24-36 hours of treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla